A 46-yeаr-оld femаle with mоderаte persistent asthma presents fоr follow-up. She reports daily symptoms and nighttime awakenings 3–4 times per week despite adherence to medium-dose inhaled fluticasone/formoterol. She uses her albuterol inhaler daily. Spirometry shows FEV₁ 68% predicted. Eosinophil count is 420 cells/µL. She has required two oral corticosteroid bursts in the past year. Which of the following is the most appropriate next step in pharmacologic management? (Select all that apply)